利伐沙班与安慰剂用于结直肠癌腹腔镜手术后延长抗血栓预防的比较
PROLAPS II 是一项随机、双盲、安慰剂对照、研究者发起的优效性研究,评估结直肠癌腹腔镜手术后延长利伐沙班预防静脉血栓栓塞的有效性和安全性。患者随机接受利伐沙班10 mg每日一次或安慰剂,术后7±2天开始用药,持续3周。主要结局事件在安慰剂组282例中发生11例,利伐沙班组287例中发生3例(3.9% vs 1.0%;比值比0.26;95%CI 0.07-0.94;log-rank P=0.032)。大出血在安慰剂组无发生,利伐沙班组2例(发生率0.7%;95%CI 0-1.0)。
要点
- 结直肠癌腹腔镜术后延长利伐沙班10 mg每日一次3周,主要结局事件发生率3.9% vs 1.0%(比值比0.26;95%CI 0.07-0.94;log-rank P=0.032)。
- 大出血发生率安慰剂组0例,利伐沙班组2例(发生率0.7%;95%CI 0-1.0)。
- 因研究药物过期,入组582例后提前终止(计划646例)。
核心结论
- 口服利伐沙班在结直肠癌腹腔镜手术后延长预防静脉血栓栓塞方面比安慰剂更有效,且未增加大出血。
研究设计与样本
- PROLAPS II 是一项随机、双盲、安慰剂对照、研究者发起的优效性研究,旨在评估结直肠癌腹腔镜手术后延长利伐沙班预防的有效性和安全性。
- 连续接受结直肠癌腹腔镜手术的患者随机接受利伐沙班(10 mg每日一次)或安慰剂,术后7±2天开始用药,持续3周。
- 所有患者从手术至随机化期间接受低分子肝素抗血栓预防。
- 因研究药物过期,入组582例后提前终止(计划646例)。
主要发现
- 主要研究结局(术后28±2天内有症状且客观确认的静脉血栓栓塞、无症状超声检测的深静脉血栓或静脉血栓栓塞相关死亡的复合终点)在安慰剂组282例中发生11例,利伐沙班组287例中发生3例(3.9% vs 1.0%;比值比0.26;95%CI 0.07-0.94;log-rank P=0.032)。
- 主要安全性结局大出血在安慰剂组无患者发生,利伐沙班组2例患者发生(发生率0.7%;95%CI 0-1.0)。
局限性
- 因研究药物过期,入组582例后提前终止(计划646例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical benefit of extended prophylaxis for venous thromboembolism (VTE) after laparoscopic surgery for cancer is unclear. The efficacy and safety of direct oral anticoagulants for this indication are unexplored. PROphylaxis of venous thromboembolism after LAParoscopic Surgery for colorectal cancer Study II (PROLAPS II) was a randomized, double-blind, placebo-controlled, investigator-initiated, superiority study aimed at assessing the efficacy and safety of extended prophylaxis with rivaroxaban after laparoscopic surgery for colorectal cancer. Consecutive patients who had laparoscopic surgery for colorectal cancer were randomized to receive rivaroxaban (10 mg once daily) or a placebo to be started at 7 ± 2 days after surgery and given for the subsequent 3 weeks. All patients received antithrombotic prophylaxis with low-molecular-weight heparin from surgery to randomization. The primary study outcome was the composite of symptomatic objectively confirmed VTE, asymptomatic ultrasonography-detected deep vein thrombosis (DVT), or VTE-related death at 28 ± 2 days after surgery. The primary safety outcome was major bleeding. Patient recruitment was prematurely closed due to study drug expiry after the inclusion of 582 of the 646 planned patients. A primary study outcome event occurred in 11 of 282 patients in the placebo group compared with 3 of 287 in the rivaroxaban group (3.9 vs 1.0%; odds ratio, 0.26; 95% confidence interval [CI], 0.07-0.94; log-rank P = .032). Major bleeding occurred in none of the patients in the placebo group and 2 patients in the rivaroxaban group (incidence rate 0.7%; 95% CI, 0-1.0). Oral rivaroxaban was more effective than placebo for extended prevention of VTE after laparoscopic surgery for colorectal cancer without an increase in major bleeding. This trial was registered at www.clinicaltrials.gov as #NCT03055026.
引用
- Becattini C, Pace U, Pirozzi F, et al. Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Blood. 2022. PMID: 35580191. doi:10.1182/blood.2022015796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。